Semaglutide is a GLP-1 receptor agonist that increases fullness, slows stomach emptying and helps control blood sugar.
What Semaglutide does and why that matters
Semaglutide copies part of a natural after-meal signal called GLP-1. It helps the body release insulin when blood sugar is high, reduces glucagon, slows food leaving the stomach and makes people feel full sooner and for longer. In everyday terms, that can mean eating less, losing weight and improving blood-sugar control. The approved benefit and instructions depend on whether the exact product is Wegovy, Wegovy HD, Ozempic or Rybelsus. [1,2]
Function evidence: Known action described in approved product labels
What patients may notice
Many patients notice that they become satisfied with smaller portions, stay full for longer or think about food less often. Over time, those changes can support weight loss; in diabetes treatment, semaglutide can also improve blood-sugar control. Not everyone experiences the same appetite change or result, and gastrointestinal effects can make treatment difficult for some people. The expected benefit, dose, device and instructions depend on the exact approved product. Wegovy, Wegovy HD, Ozempic and Rybelsus should not be treated as interchangeable versions of one generic protocol. [1,2,3]
What supports this description: Approved-product labels and human clinical outcomes
Semaglutide Dosing status
Dose: Product specific: Wegovy HD includes an FDA-approved 7.2 mg once-weekly dose for eligible adults; use the current label and prescription. [1,2] | Frequency: Follow the exact product label and prescription. | Cycle: Prescription treatment duration is individualized; do not invent a cycle. | Route: Product and presentation specific.
Preparation: Do not apply a generic vial recipe. Follow the instructions for the exact dispensed presentation..
Semaglutide is the active ingredient in several FDA-approved prescription products. Each has its own indication, strength, route and instructions. On March 19, 2026, FDA approved a 7.2 mg once-weekly dose of Wegovy HD for eligible adults with obesity. This does not make a compounded preparation interchangeable with any of the branded products. [1,2,3]
Semaglutide Effects
Obesity treatment. Approved Wegovy products are used with diet and physical activity for labeled populations. Wegovy HD 7.2 mg is a distinct higher-dose presentation approved in 2026 for eligible adults; prescribers should use the current label. [1,2]
Product identity matters. Ozempic, Wegovy, Wegovy HD and Rybelsus are not interchangeable instructions: their indications, routes, concentrations, devices, and storage differ. [1,2]
Semaglutide Side Effects
Approved-label warnings. Semaglutide labels include boxed and other warnings, contraindications, drug-interaction information, and product-specific handling. This page does not replace the current Medication Guide or prescriber instructions. [2]
Compounded-product differences. Compounded drugs are not FDA-approved. FDA has warned about dosing errors and says salt forms such as semaglutide sodium or acetate are different active ingredients from those in approved drugs. [3]
Frequently Asked Questions About Semaglutide
What are the current approved Wegovy doses?
Standard Wegovy remains available in its labeled strengths, and FDA approved Wegovy HD 7.2 mg once weekly in March 2026 for eligible adults with obesity. Use the current label and prescriber’s escalation plan for the exact product. [1,2]
Is compounded semaglutide automatically the same as Wegovy or Ozempic?
No. Compounded drugs are not FDA-approved, may use different concentrations and containers, and FDA says semaglutide salt forms are different active ingredients from the approved base form. [3]
Evidence
FDA-approved medicines; instructions are product and indication specific. Semaglutide is the active ingredient in several FDA-approved prescription products. Each has its own indication, strength, route and instructions. On March 19, 2026, FDA approved a 7.2 mg once-weekly dose of Wegovy HD for eligible adults with obesity. This does not make a compounded preparation interchangeable with any of the branded products. [1,2,3]
Approval status: FDA-approved only for the named products and labeled uses. [1,2,3]
References
U.S. Food and Drug Administration FDA Approves Higher Dose Semaglutide (Wegovy HD) , 2026. Source
U.S. Food and Drug Administration Wegovy and Wegovy HD prescribing information , 2026. Source
U.S. Food and Drug Administration FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss , 2026. Source
Storage
Exact dispensed product: Follow its current label and pharmacy instructions. Do not infer stability from another formulation or from the CDC multidose-vial convention.
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
